Tarrytown, NY-based Regeneron Pharmaceuticals, Inc. (REGN – Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol.

Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. The approval of two new drugs will also boost the sales. The FDA approved Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis (AD). Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was also approved in the United States for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs.

In this scenario, investor focus should remain on the performance of Eylea and uptake of Dupixent apart from the usual top-and bottom-line numbers.

Regeneron’s performance has been mixed so far. In the last four reported quarters, it surpassed earnings estimates on three occasions and missed in one. Overall, the company has recorded an average positive earnings surprise of 9.15%.

Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise

 Currently, Regeneron has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Regeneron’s first-quarter 2018 earnings topped expectations. Our consensus called for EPS of $4.51 and the company reported EPS of $4.67.

Revenues: Revenues in the reported quarter however fell short of expectations. Regeneron posted revenues of $1.51 billion, compared to our consensus estimate of $1.53 billion.

Key Stats: Eylea net sales increased 15.2% year over year to $984 million in the United States. Dupixent sales came in at $131 million.